TABLE 2.
Change in outcome measures (SD) at 8 and 26 week follow‐up a
| Xylitol | Saline | Control | ||||
|---|---|---|---|---|---|---|
| 8 weeks | 26 weeks | 8 weeks | 26 weeks | 8 weeks | 26 weeks | |
| (n = 14) | (n = 14) | (n = 14) | (n = 12) | (n = 12) | (n = 11) | |
| SNOT‐20 b | 34.2 (18.6) | 32.3 (17.9) | 38.0 (20.2) | 32.2 (16.6) | 44.2 (8.6) | 44.1 (20.5) |
| Δ c/t baseline | −16.9 (4.9)** | −18.9 (4.9)** | −8.8 (5.0) | −16.9 (5.3)** | −3.4 (5.3) | −3.5 (5.6) |
| Δ c/t control | −13.5 (7.2) | −15.4 (7.4)* | −5.3 (7.3) | −13.4 (7.7) | ||
| (n = 14) | (n = 14) | (n = 14) | (n = 12) | (n = 12) | (n = 11) | |
| SF‐36 b | 52.0 (19.8) | 57.3 (21.5) | 63.6 (19.8) | 66.3 (19.2) | 61.9 (15.2) | 63.3 (20.6) |
| Δ c/t baseline | 1.1 (3.5) | 6.4 (3.5) | 3.9 (3.6) | 7.3 (3.6) a | −0.1 (3.8) | 2.0 (4.0) |
| Δ c/t control | 1.2 (5.2) | 4.4 (5.3) | 4.0 (5.2) | 5.3 (5.5) | ||
| (n = 12) | (n = 9) | (n = 14) | (n = 12) | (n = 11) | (n = 8) | |
| MFI‐20 b | 59.8 (7.1) | 61.1 (4.3) | 60.8 (7.0) | 59.3 (5.4) | 61.9 (5.6) | 73.5 (16.9) |
| Δ c/t baseline | 0.6 (2.4) | 1.9 (2.8) | 0.9 (2.3) | −1.4 (2.4) | 0.5 (2.5) | 10.4 (3.0) |
| Δ c/t control | 0.1 (3.5) | −8.5 (4.0) | 0.4 (3.4) | −11.7 (3.8) | ||
| (n = 14) | (n = 13) | (n = 14) | (n = 12) | (n = 12) | (n = 11) | |
| Sleep b | 38.7 (9.2) | 35.1 (9.8) | 41.5 (10.7) | 41.2 (8.8) | 42.8 (7.1) | 41.5 (6.9) |
| Δ c/t baseline | −3.2 (2.2) | −6.3 (2.3)** | −3.5 (2.2) | −4.4 (2.3) | 1.2 (2.4) | −0.0 (2.5) |
| Δ c/t control | −4.4 (3.2) | −6.3 (3.3) | −4.8 (3.2) | −4.4 (3.4) | ||
| (n = 13) | (n = 13) | (n = 14) | (n = 12) | (n = 12) | (n = 11) | |
| Wheezing b | 21.6 (4.1) | 22.9 (3.0) | 20.9 (5.9) | 20.8 (5.0) | 22.6 (2.7) | 21.3 (4.0) |
| Δ c/t baseline | 0.4 (1.0) | 1.8 (1.0) | −0.5 (1.0) | −0.4 (1.0) | 1.0 (1.0) | −0.2 (1.1) |
| Δ c/t control | −0.6 (1.4) | 1.9 (1.4) | −1.5 (1.4) | −0.2 (1.5) | ||
| Antibiotic % c | 7.4 (1.2)* | 0.2 (0.8) | 0.8 (2.3) | |||
| Other sinus medication % c | 19.5 (32.4)* | 8.2 (21.4)* | 53.3 (43.6) |
Abbreviations: Δ c/t, “change compared to”; MFI, multidimensional fatigue index; SF‐36, Short‐Form 36; SNOT‐20, sino‐nasal outcomes test‐20.
a
All estimates control for age and gender.
b
SNOT‐20, SF‐36, MFI; Sleep and Wheezing scales are 0‐100 points.
c
Antibiotic and Other Sinus Medication are percentage of study days on which participant took the medication.
*
P < .05.
**
P < .01.